Eli Lilly

Higher dose of Pfizer-Lilly drug helps reduce back pain in study
Higher dose of Pfizer-Lilly drug helps reduce back pain in study
Yahoo/Reuters
Pfizer
Eli Lilly
chronic low back pain
low back pain
clinical trials
tanezumab
opioid alternatives
Flag link:
Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo
Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo
Yahoo/Reuters
Bayer
Vitrakvi
cancer
Eli Lilly
Loxo Oncology
Flag link:
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
glimepiride
linagliptin
Tradjenta
type 2 diabetes
clinical trials
Flag link:
Pharma companies clear the R&D decks in Q4
Pharma companies clear the R&D decks in Q4
Pharmaforum
R&D
GSK
Sanofi
Eli Lilly
Roche
Gilead Sciences
Flag link:
Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal
Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal
TheStreet.com
Eli Lilly
earnings
M&A
Loxo Oncology
Flag link:
Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials
Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials
BioSpace
Eli Lilly
Incyte
olumiant
atopic dermatitis
clinical trials
Flag link:
Here's Why Array BioPharma Jumped 31% in January
Here's Why Array BioPharma Jumped 31% in January
Motley Fool
Array Biopharma
Eli Lilly
Braftovi
Mektovi
Flag link:
Upcoming events – Ascendis and Lilly hope for growth with pivotal data
Upcoming events – Ascendis and Lilly hope for growth with pivotal data
EP Vantage
Ascendis
clinical trials
pediatric growth hormone deficiency
TransCon hGH
Eli Lilly
olumiant
eczema
Flag link:
Eli Lilly Loxo Oncology Transaction Clears A Hurdle
Eli Lilly Loxo Oncology Transaction Clears A Hurdle
CP Wire
Eli Lilly
Loxo Oncology
M&A
Flag link:
Eli Lilly Loxo Oncology Transaction Clears A Hurdle
Eli Lilly
Loxo Oncology
M&A
Flag link:
Even with new competition, Botox can hold its own in growing migraine field: Allergan executives
Even with new competition, Botox can hold its own in growing migraine field: Allergan executives
Fierce Pharma
Allergan
Botox
Amgen
Eli Lilly
Teva Pharmaceuticals
migraines
Flag link:
Pfizer and Lilly’s tanezumab succeeds in second phase 3 osteoarthritis pain trial
Pfizer and Lilly’s tanezumab succeeds in second phase 3 osteoarthritis pain trial
Pharmaceutical Business Review
Pfizer
Eli Lilly
tanezumab
clinical trials
osteoarthritis pain
osteoarthritis
Flag link:
Last week in biopharma - earnings reports, drug pricing, a new GENE CEO and more
Last week in biopharma - earnings reports, drug pricing, a new GENE CEO and more
CP Wire
earnings
drug pricing
Genentech
Eli Lilly
Medtronic
Roche
M&A
Takeda
GSK
FDA
Flag link:
Last week in biopharma-earnings reports, drug pricing, a new GENE CEO and more
earnings
drug pricing
Genentech
Eli Lilly
Medtronic
Roche
M&A
Takeda
GSK
FDA
Flag link:
CVS to cover migraine drugs from Teva, Lilly; excludes Amgen
CVS to cover migraine drugs from Teva, Lilly; excludes Amgen
Reuters
CVS Health
migraines
Amgen
Teva Pharmaceutical
Eli Lilly
Aimovig
Ajovy
Emgality
Flag link:
In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions
In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions
Endpoints
Eli Lilly
cancer
Lartruvo
FDA
EMA
Flag link:
A flashy 2019 start to pharma M&A, but will it last?
A flashy 2019 start to pharma M&A, but will it last?
Biopharma Dive
M&A
Celgene
Bristol-Myers Squibb
Eli Lilly
Loxo Oncology
Flag link:
Lilly’s second immune-oncology candidate using Zymeworks’ Azymetric platform to start clinical trials
Lilly’s second immune-oncology candidate using Zymeworks’ Azymetric platform to start clinical trials
Pharmaceutical Business Review
Eli Lilly
Zymeworks
drug development
Azymetric platform
Flag link:
On heels of Loxo buy, Lartruvo setback deals a blow to Lilly's oncology hopes
On heels of Loxo buy, Lartruvo setback deals a blow to Lilly's oncology hopes
Fierce Pharma
Eli Lilly
Lartruvo
soft tissue sarcoma
clinical trials
Flag link:
No bidding war for Loxo, so did Lilly overpay? Don’t rush to judgment, analysts say
No bidding war for Loxo, so did Lilly overpay? Don’t rush to judgment, analysts say
Fierce Pharma
Eli Lilly
Loxo Oncology
M&A
Flag link:

Pages